share_log

Rayont Inc- RAYT- Reports 10-Q for the Six -Month Ending December 31, 2022, Financial Results.

Rayont Inc- RAYT- Reports 10-Q for the Six -Month Ending December 31, 2022, Financial Results.

Rayont Inc-RAYT-公布截至2022年12月31日的六个月的10季度财务业绩。
GlobeNewswire ·  2023/02/15 05:05

Palo Alto, California, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the six-month ended December 31, 2022.

加利福尼亚州帕洛阿尔托,2023年2月14日(GLOBE NEWSWIRE)——国际个性化自然医疗保健公司雷昂公司(“Rayont” 或 “公司”)(OTC PINK: RAYT)今天公布了截至2022年12月31日的六个月的财务业绩。

Business Highlights Within the Six-Month ended December 31, 2022:

内部业务亮点 -本月已结束 十二月 31,2022:

Ms. Marshini Moodley, CEO and CFO, said, "We recorded an increase in both the revenue and gross profit for the period ended December 31, 2022 compared to same period last year, mainly due to acquisition of the business of No More Knots Pty Ltd, No More Knots (Newmarket) Pty Ltd, No More Knots (Taringa) Pty Ltd, Ipswich Massage and Tugun Compounding Pharmacy under Health Script Pty Ltd.

首席执行官兼首席财务官马希尼·穆德利女士表示:“与去年同期相比,截至2022年12月31日的期间,我们的收入和毛利均有所增长,这主要是由于收购了Health Script旗下No More Knots Pty Ltd、No More Knots(Newmarket)私人有限公司、No More Knots(Taringa)Pty Ltd、Ipswich Massage 和 Tugun Compounding Pharmacy 的业务 Pty Ltd.

Six-month Ending December 31, 2022, Financial Results:

-月结束十二月 31,2022财务业绩:

    Six Months Ended December 31,  
    2022     2021  
Revenues   $ 2,788,102     $ 1,361,887  
Gross Profit   $ 1,686,183     $ 671,421  
    截至12月31日的六个月  
    2022     2021  
收入   $ 2,788,102     $ 1,361,887  
毛利   $ 1,686,183     $ 671,421  

Improved Balance Sheet Results

资产负债表业绩改善

      December 31,
2022
      June 30,
2022
 
Cash   $ 10,652     $ 185,782  
Total Assets   $ 10,257,537     $ 14,193,235  
Total Liabilities   $ 4,018,703     $ 9,099,623  
Total Stockholders' Equity   $ 6,238,834     $ 5,093,612  
      十二月三十一日
2022
      6月30日,
2022
 
现金   $ 10,652     $ 185,782  
总资产   $ 10,257,537     $ 14,193,235  
负债总额   $ 4,018,703     $ 9,099,623  
股东权益总额   $ 6,238,834     $ 5,093,612  


Marshini Moodley added, "Our quarterly performance reflecting decreased total asset portfolio and total liabilities mainly as result of the sale of three subsidiaries of the group that included mostly the land, properties and loans related with those properties. Due to that, the working capital is improved as there was a working capital deficit of $83,884 on June 30, 2022 and working capital of $1,237,993 on December 31, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the quarter".


Marshini Moodley补充说:“我们的季度业绩反映了总资产组合和总负债的减少,这主要是由于出售了该集团的三家子公司,主要包括与这些物业相关的土地、房地产和贷款。因此,由于营运资金赤字为,营运资金得到改善 $83,884 2022 年 6 月 30 日,营运资金为 $1,237,993 2022 年 12 月 31 日。我们的现金储备减少了,这是由于为支付公司在本季度进行的不同投资而收到的资本投资和还本付息贷款利息”。

Strategies for Growth

增长策略

During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:

在本财政年度,我们将继续开展多项旨在改善Rayont Inc整体业绩的关键活动,即:

  • Continue to consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
  • Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
  • Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
  • 继续将Prema Life的运营与Tugun Compounding Pharmacy的运营合并,以推动这两项业务的成本降低和效率。
  • 为全球自然疗法者推出Health Script远程医疗平台,主要市场集中在澳大利亚和美国。
  • 继续进行规模较小的收购,以促进整个集团的收入增长和协同效应。我们预计,迄今为止的收购将有助于本财政年度的显著收入和利润增长。

These activities are being worked on and we will communicate their completions as we achieve them.

这些活动正在进行中,我们将在完成这些活动后告知其完成情况。

Disclosure Regarding the Financial Reports Provided in the Form 10-Q

披露 R关于那个 F财务的 R出口 已提供 在 10-Q 表格中

The auditor's review for current version of the Form 10Q has not been completed due to the fact that the valuation report for the acquisition of the business of Ipswich Massage, Prema Life and Tugun Compounding Pharmacy by an independent expert that not been completed. The company is in process of procuring these reports.

审计师对当前版本的10Q表格的审查尚未完成,这是因为独立专家收购Ipswich Massage、Prema Life和Tugun Compounding Pharmacy业务的估值报告尚未完成。该公司正在获取这些报告。

Once the auditor's review is ready, the Company will file an amendment to its Form 10-Q.

审计师的审查准备就绪后,公司将提交其10-Q表的修正案。

About Rayont Inc.

A比赛雷蒙特公司

Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.

Rayont, Inc.(RAYT)是一家自2011年成立以来在美国内华达州注册的上市公司。2018 年,公司重新定位,专注于个性化自然医疗行业。

Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.

Rayont使用DNA、微生物组、虹膜学和其他测试等科学工具,为我们运营的市场中的患者提供天然补充和替代药物产品、服务和治疗的个性化诊断、处方和治疗。

For further information, please visit 

欲了解更多信息,请访问

SAFE HARBOR

安全港

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

本新闻稿中的某些陈述可能包含1933年《证券法》第175条所指的前瞻性信息,受1934年《证券交易法》第3b-6条的约束,并受这些规则建立的安全港的约束。除事实陈述外,本新闻稿中包含的所有陈述,包括但不限于有关公司未来潜在计划和目标的陈述,均为涉及风险和不确定性的前瞻性陈述。无法保证此类陈述会被证明是准确的,其他结果和进一步的事件可能与此类声明中的预期存在重大差异。未来事件和实际结果可能与前瞻性陈述中阐述、所考虑或所依据的事件和实际结果存在重大差异。

Company Contact:
Investor Relations
ir@rayont.com

公司联系人:
投资者关系
ir@rayont.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发